Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Other Current Assets?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Other Current Assets is 
$2.0B (1Y +223% )

ALXN Stock Price & Other Current Assets

Other Current Assets for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Other Current Assets

chevron_right 2021 $651.0M +812x
( +28.2% / year avg)
chevron_left 1995 $800.0K
vertical_align_top Peak $1.3B -
vertical_align_bottom Bottom 0.0
arrow_drop_up # Up Years 16 16 of 27
years up.
arrow_drop_down # Down Years 9
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or +0.06x the rate relative to it's other current assets over the same period.
  • If ALXN grows it's stock at the same rate as it's other current assets (+28.2%/year) , it's stock price will grow +1,199% and hit $1303.74 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 16 years (0%) it's other current assets were also up.
  • ALXN Historical Other Current Assets Table
    in $ million
    Year Other Current Assets YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $651 7.6% - -
    4/1/2020 $605 - - -
    4/1/2019 $0 - - -
    4/1/2018 $0 - - -
    4/1/2017 $0 -100.0% - -
    4/1/2016 $37 -92.9% - -
    4/1/2015 $530 39.2% - -
    4/1/2014 $380 44.8% - -
    4/1/2013 $263 -55.5% - -
    4/1/2012 $590 -53.2% - -
    4/1/2011 $1,263 49.4% - -
    4/1/2010 $845 233.9% - -
    4/1/2009 $253 1055.9% - -
    4/1/2008 $21 - - -
    4/1/2007 $0 -100.0% - -
    4/1/2006 $12 189.1% - -
    4/1/2005 $4 6.1% - -
    4/1/2004 $3 29.5% - -
    4/1/2003 $3 17.8% - -
    4/1/2002 $2 -87.1% - -
    4/1/2001 $19 -26.4% - -
    4/1/2000 $26 7608.6% - -
    4/1/1999 $0 250.0% - -
    4/1/1998 $0 -99.4% - -
    4/1/1997 $16 -17.9% - -
    4/1/1996 $19 2337.5% - -
    4/1/1995 $0 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Current assets have a lifespan of one year or less, meaning they can be converted easily into cash. Such asset classes include cash and cash equivalents, accounts receivable and inventory.

    Other current assets are assets that are not specified in the financial statement.

    For more detailed definitions, please see Investopedia.